𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen: Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ, Department of Urology, Division of Nuclear Medicine, New York-Presbyterian Hospital/Weill Medical College of Cornell University, New York, NY

✍ Scribed by Mark P Ritter

Book ID
116955616
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
14 KB
Volume
22
Category
Article
ISSN
1078-1439

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of yttrium-90—labeled anti
Phase I trial of yttrium-90—labeled anti—prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer: Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH, Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY. J Clin Oncol 2004;22:2522–31
✍ Peter R. Carroll 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 44 KB
Radiolabeled monoclonal antibodies speci
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor: Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH, Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, NY. J Nucl Med 2003;44:610–617
✍ Peter R Carroll 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 21 KB